Why the study?
Current literature remains inconclusive on whether relative HDL deficiency drives the development of fatty liver disease in humans, despite in vitro observations suggesting protection against NAFLD-like lipid accumulation.
Does pharmacological HDL level and/or function modulation prevent the development of fatty liver disease?
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Inconclusive evidence precludes HDL modulation for fatty liver prevention; leaves open causal role and need for targeted trials.
Although in vitro observations suggest causality between HDL formation by hepatocytes and protection against NAFLD-like lipid accumulation, current literature remains inconclusive on whether relative HDL deficiency is actually driving the development of fatty liver disease in humans. In light of the current obesity pandemic and the associated marked rise in NAFLD incidence, it is of clear scientific and societal interest to gain further insight into the relationship between HDL-cholesterol levels and fatty liver development to potentially uncover the therapeutic potential of pharmacological HDL level and/or function modulation.
No takes yet. Share an insight, caveat, or question.
Hoekstra et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: